Flutura accelerates Lupin to digitally transform their operations using AI
A digital data foundation will host data for all of Lupin's operational processes.
Bangalore: Flutura Business Solutions LLC, an Industrial IoT Intelligence provider, has announced the collaboration with global pharma major Lupin Limited to accelerate its digital transformation and automation journey.
Lupin and Flutura will collaborate to create a massive pharmaceutical data lake as the foundation for configuring digital twins of mission critical pharmaceutical processes as well as bolt-on battle-tested AI applications at scale that can sense and respond to events in real-time.
A digital data foundation will host data for all of Lupin's operational processes. Starting with Manufacturing, Quality, and Sales & Marketing functions, it will expand to finance and supply chain function until all the information converges into a Central Data Lake.
"We were seeking a solution that is scalable and flexible to meet the range of disparate data that needs to be stored, Cerebra was the most suitable choice. Cerebra Analytics' Work Bench (AWB) can complement our operational experts (citizen data scientists) in a way that will add significant value to our business," said Narendra Saini, Chief Digital Officer at Lupin.
Flutura will support Lupin in accelerating its AI journey and develop advanced analytics and high value use cases in order to uncover actionable insights from the massive data lake.
"We like working with visionary customers who are looking to break new barriers in value creation. We were truly inspired when Lupin shared their transformative, yet pragmatic vision for digitalization in Lupin," said Srikanth Muralidhara, Chief Customer Officer at Flutura.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas.
Read also: Lupin gets USFDA nod for generic equivalent of Vemlidy Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.